Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Veradermics announces oversubscribed $150M Series C financing

by mariel | Oct 16, 2025 | Portfolio News

Veradermics closed an oversubscribed $150 million Series C financing led by SR One to fund Phase 3/registrational work for its lead program.

Zenas BioPharma and InnoCare announce “transformational” license agreement (MS + autoimmune pipeline)

by mariel | Oct 8, 2025 | Portfolio News

Zenas announced a license agreement for global development/commercialization rights to orelabrutinib for MS and additional autoimmune assets; Phase 3 activity in progressive MS was underway/initiating.

Somatus announces mortality reduction results from new kidney disease care model study

by mariel | Oct 1, 2025 | Portfolio News

Somatus reported results from a new study showing a statistically significant reduction in mortality for kidney disease patients, reinforcing outcomes from its care model.

Roche to acquire 89bio (ETNB) in deal valued up to ~$3.5B

by mariel | Sep 17, 2025 | Portfolio News

Roche entered into a definitive merger agreement to acquire 89bio, including $14.50/share cash at closing plus a contingent value right tied to milestones.

Kestra reports Q1 FY26 results; increases full-year FY26 revenue guidance

by mariel | Sep 11, 2025 | Portfolio News

Kestra reported ~$19M revenue in Q1 FY26 (+52% YoY), improved gross margin, and increased FY26 revenue guidance to $88M.

Mirum completes enrollment in Phase 2b VISTAS study of volixibat

by mariel | Sep 8, 2025 | Portfolio News

Mirum announced completion of enrollment in the Phase 2b VISTAS study of volixibat in PSC cholestatic pruritus; topline data expected in 2Q 2026.
« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • Twitter
  • Google
  • RSS
footer-logo

LP Login

© 2026 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer